SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI is trending as the community speculates on potential catalysts and future gains, with some mentioning a possible Binance or Robinhood listing. Bullish investors are actively buying the dips, citing the project's utility and strong community as reasons for their optimism. Others highlight the potential for significant growth, drawing comparisons to previous meme coin successes and the overall positive sentiment surrounding the Base ecosystem.

this coin is scarce

SCARCE CRYPTO is trending as community members express excitement and encourage others to buy, emphasizing the coin's scarcity. Discussions highlight a controlled chart and smooth range, with some suggesting the coin is poised for a breakout. The coin is also being mentioned alongside other cryptos such as SOL and BTC.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet ($STRK) is trending as community members highlight its potential role in scaling Bitcoin and Ethereum through zero-knowledge proofs, with some drawing comparisons to Zcash ($ZEC). Discussions also focus on Starknet's ecosystem growth, recent technical upgrades including the S-Two STARK prover, and incentives for Bitcoin liquidity staking, suggesting a growing interest in its capabilities and future prospects.

AKUMA INU was born in BASE, the underground arena that has come to be known amongst crypto degens as "The Origin Pit". Forged in the frenzied fires of market volatility, AKUMA INU has emerged as the ultimate embodiment of the degen spirit - wild, unyielding, and relentless in the pursuit of crypto supremacy. Akuma Inu is here on Base chain, and he is here to stay. Come join us on our amazing journey!

Akuma Inu

Akuma Inu is trending as a micro-cap gem with a low market capitalization gains traction within the community. Discussions highlight its potential for explosive growth, drawing comparisons to its previous all-time highs. Community members are pointing out the coin's potential for significant returns.

DoubleZero is a high-performance global network of independently contributed links, purpose-built for blockchain and other distributed systems. It provides direct, low-latency routing that strengthens validator performance and supports faster, fairer participation worldwide.  2Z Tokens are used to access the network’s connectivity service, and, on the other side, reward network contributors and resource providers based on performance and reliability. 2Z Tokens can also be staked to enhance the security of the network.

DoubleZero

DoubleZero ($2Z) is trending amid discussions about its potential in crypto telecom, particularly its use of fiber optics. Community members are weighing in on its recent price action, with some citing a new listing on a major crypto exchange driving volume, while others debate its legitimacy.

Hyperion DeFi, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in Laguna Hills, CA.

Hyperion DeFi Inc.

HYPD is trending as investors weigh the potential of its crypto treasury strategy against concerns about share dilution and past management issues. Community discussions center on recent earnings, guidance, and partnerships, with some questioning the company's direction and shareholder value while others remain optimistic about its focus on the Hyperliquid ecosystem and the HYPE token. Technical analysis suggests range-bound trading and high volatility, adding to the uncertainty surrounding the stock's near-term trajectory.

What is the project about?   Horizen is a modular privacy-first platform designed to make privacy technology, such as zero-knowledge proofs and TEEs accessible and usable across the web. Originally launched in 2017 as a fair launch, non-ICO project, Horizen is now undergoing a major evolution with the launch of Horizen 2.0, a next-generation Layer 3 (L3) appchain deployed on Base, the Ethereum Layer 2 developed by Coinbase.  Horizen 2.0 is built as an Ethereum-aligned Layer 3 appchain on Base, inheriting Ethereum's security while implementing its own application-level integrity guarantees.    Key components of Horizen’s security model include:  Ethereum-Aligned Security: As an appchain deployed on Base, Horizen 2.0 benefits from Base’s rollup security and settlement on Ethereum, ensuring robust finality and composability with other L2 and L3 applications.  Simplified and Secure Architecture: Unlike Horizen’s previous iterations (which used a hybrid PoW/PoS model), Horizen 2.0 focuses on application-level security, decentralization of its privacy layers, and composability with existing infrastructure — reducing complexity and increasing user safety.  Decentralized Privacy Stack: Horizen’s focus on decentralizing privacy infrastructure (e.g., decentralized proof generation) allows for modular, secure applications that uphold data confidentiality without compromising performance.    What makes your project unique?  Privacy-first Approach: Horizen integrates a diverse stack of privacy-enhancing technologies (PETs) — including zero-knowledge proofs (ZKPs), trusted execution environments (TEEs), attribute-based encryption (ABE), multi-party computation (MPC), and fully homomorphic encryption (FHE) — to deliver scalable, flexible, and future-ready privacy solutions across its platform.  First Privacy Appchain on Base: As an L3 on Base, Horizen benefits from Ethereum’s security and Base’s scalability, while enabling a privacy layer for any app on the network. This unlocks new possibilities for private identity, DeFi, onchain gaming, and compliant confidential transactions.  Zero-Knowledge, Without the Trade-Offs: Horizen 2.0 scales ZK privacy and verification by integrating with leading zk infrastructure providers such as Fermah, zkVerify, and Singularity, optimizing proof generation for performance, cost-efficiency, and developer usability.  Token Utility Expansion: ZEN’s updated tokenomics allocates 5 million unminted tokens toward strategic ecosystem growth. ZEN powers DAO governance, serves as a payment token in privacy apps, and supports a sustainability fund to accelerate privacy innovation.  Developer-Centric Design: With EVM compatibility, privacy-friendly tooling, and the ability to embed privacy directly into smart contracts, Horizen allows developers to build privacy-first apps without requiring deep cryptographic expertise.  DAO-Led Governance: Governed by the Horizen DAO and shaped through community proposals (ZENIPs), Horizen is evolving as a fully decentralized protocol with transparent development and decision-making.    What can your coin/token be used for?  Horizen 2.0 delivers performance, privacy, and scalability for developers building privacy-enabled and compliance-friendly applications, with significantly reduced cost and latency.  At the core of the ecosystem is ZEN, the native utility token used for governance, accessing privacy services, and fueling zkApp interactions. With its migration to Base, ZEN becomes an ERC-20 token, improving liquidity, interoperability, and composability across the broader Ethereum ecosystem.

ZenCash

ZEN Crypto is trending as traders discuss its potential for significant gains, drawing comparisons to ZCash ($ZEC). Community members are actively watching key price levels, anticipating a pump and citing its limited supply as a factor for potential growth. The migration to Base chain and listing on OKX exchange is also a key catalyst.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders discuss potential market volatility catalysts, including housing market concerns, foreclosure rates, and geopolitical risks. Community members are actively sharing options strategies and hedging techniques, while also debating the differences between UVIX and similar volatility products like UVXY. Some traders express skepticism about current market valuations, anticipating a potential market correction and increased volatility.

Tidal Trust II - YieldMax TSLA Option Income Strategy ETF

YieldMax TSLA Option Income Strategy ETF

TSLY is trending due to news of a potential reverse split and discussions around its structural underperformance and NAV erosion. The community is weighing the pros and cons of DRIP (dividend reinvestment plan) and dollar-cost averaging amid concerns about the ETF's long-term trajectory and the impact of covered calls in capturing upside. Many are also reacting to the latest dividend announcement which was viewed as quite low.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending due to a surge in stock price, fueled by optimism around its energy storage solutions and potential benefits from the AI-driven data center boom. Community discussions highlight the undervaluation of CSIQ compared to its assets, particularly its stake in CSI Solar, and speculate about a potential sale of Recurrent Energy. The stock's recent performance has also led to discussions of a possible short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Day One Biopharmaceuticals Sees Unusually Large Options Volume (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) was the recipient of unusually large options trading on Thursday. Stock investors purchased 3,055 call options on the stock. This is...

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down - Here's Why

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down - Time to Sell...

<ul class="summary-bullets"><li>Mersana surged even as multiple firms downgraded the stock following Day One’s acquisition agreement.</li><li>Analysts said competing bids are unlikely and noted Day One’s offer reflects confidence in Mersana’s assets.</li><li>Retail traders called the deal a bargain for Day One and highlighted Mersana’s broader pipeline value.</li></ul>Mersana Therapeutics logged its strongest trading session on record on Thursday, soaring even as a long list of Wall Street firms downgraded the stock after Day One Biopharmaceuticals agreed to acquire the company in a deal that could be worth up to $285 million.Day One Biopharmaceuticals closed down 14% on Thursday, while Mersana Therapeutics finished the session up 209%.<h2 class="st-heading-2">Analysts Weigh In On Day One’s Bid</h2>William Blair downgraded Mersana to ‘Market Perform’ from ‘Outperform’, saying it views it as unlikely that another bidder will emerge.Guggenheim cut its rating to ‘Neutral’ from ‘Buy’, while LifeSci Capital shifted its view to ‘Market Perform’ from ‘Outperform.’ Leerink moved the stock to ‘Market Perform’ from ‘Outperform’ and set a $29 price target. Truist downgraded Mersana to ‘Hold’ from ‘Buy’ and lowered its target to $30.75 from $36, saying it believes the deal will go through and estimating the CVR’s value at $5.75. BTIG lowered its rating to ‘Neutral’ from ‘Buy’, and Wedbush also cut the stock to ‘Neutral’ from ‘Outperform.’Oppenheimer said Day One paying up to $285 million for Mersana “is interesting.” The firm noted the acquisition “wasn't on the short list,” and said management had been “talking down PTK7,” and questioned whether Emi-Le may be positioned as its replacement. Oppenheimer added that Day One could have obtained a comparable asset from China at a lower cost and said the offer suggests management is “seeing something in Emi-Le.” The firm reiterated a ‘Perform’ rating on Day One.<h2 class="st-heading-2">Deal Terms</h2>Under the merger agreement, Day One will launch a tender offer within 10 business days of Nov. 12. The deal requires that a majority of Mersana’s shares be tendered for the transaction to proceed, after which any remaining shares would be acquired in a follow-on merger for the same consideration. Once completed, Mersana would become a wholly owned subsidiary of Day One, and its stock would be delisted.&nbsp;The agreement received unanimous board approval, and holders representing about 8.5% of outstanding shares, including executives, directors, and Bain Capital Life Sciences affiliates, have signed support agreements to tender their shares.<h2 class="st-heading-2">Legal Review</h2>Separately, law firm Ademi &amp; Fruchter said it is reviewing the deal for potential breaches of fiduciary duty, citing insider benefits, deal protection,s and limits on competing offers.<h2 class="st-heading-2">Stocktwits Traders Flag ‘Cheap’ Valuations</h2>On Stocktwits, retail sentiment for both Mersana and Day One was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said, “If they were able to buy Mersana Therapeutics ($MRSN), they could easily buy $CHRS; I'm sure many companies are interested, it's very cheap.”<stembedurl>https://stocktwits.com/Sarandon/message/636088418</stembedurl>Another user argued that Day One is getting what they called “a very good bargain” in the acquisition, saying the company is “effectively getting the entire pipeline of Mersana for about $40 million” and adding, “I am buying the stock.”<stembedurl>https://stocktwits.com/Itinerant/message/636101103</stembedurl>A third user noted that while many investors had expected Day One to be a buyout target, in this deal the company instead acted as “Apex predator,” adding that it would be “interesting to watch further manifestations in this new constitution.”<stembedurl>https://stocktwits.com/GeniusLoci/message/636078018</stembedurl><a href="https://stocktwits.com/symbol/MRSN">Mersana’s stock</a> has more than tripled so far in 2025, while&nbsp;<a href="https://stocktwits.com/symbol/DAWN">Day One’s stock</a> has climbed 35% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mersana’s stock (MRSN) has more than tripled so far in 2025, while Day One’s stock (DAWN) has climbed 35% over the same period. (Photo credit: Getty Images)

Mersana Therapeutics Stock Explodes Over 200% To Notch Best Day Ever As $285M Buyout Trumps Analyst Downgrades: Retail Cheers ‘Very Good Bargain’

Mersana surged even as multiple firms downgraded the stock following Day One’s acquisition agreement.

Equity

Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout

Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug portfolio.read more...

Mersana Therapeutics To Be Acquired By Day One Biopharmaceuticals For Up To $285 Mln

(RTTNews) - Mersana Therapeutics, Inc. (MRSN), a biopharmaceutical company, Thursday, announced that it has entered a definitive agreement to be acquired by Day One Biopharmaceuticals through a...

<ul class="summary-bullets"><li>Day One will purchase Mersana for a total consideration of up to $55.25 per share.&nbsp;</li><li>The transaction is expected to close by the end of January 2026, and Day One expects to finance it with existing cash resources.&nbsp;</li><li>The acquisition will add antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) to Day One’s cancer portfolio.</li></ul>Day One Biopharmaceuticals, Inc. (DAWN) said on Thursday that it has signed a definitive merger agreement to acquire Mersana Therapeutics (MRSN) for up to $285 million to expand its oncology portfolio.Brisbane-based Day One will commence a tender offer to acquire all of the outstanding shares of Mersana common stock for $25 per share in cash at closing, in addition to a contingent value right that allows holders to receive up to an aggregate of $30.25 per CVR upon the completion of certain milestones for a total consideration of up to $55.25 per share.The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday. The transaction is expected to close by the end of January 2026, and Day One <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/13/3187097/0/en/Day-One-to-Acquire-Mersana-Therapeutics-to-Advance-Mission-to-Bring-New-Medicines-to-People-of-All-Ages-with-Life-Threatening-Diseases.html">expects</a> to finance it with existing cash resources.<a href="https://stocktwits.com/symbol/MRSN">MRSN shares</a> traded 200% higher in the pre-market session at the time of writing while <a href="https://stocktwits.com/symbol/DAWN">DAWN shares</a> dropped 12%.<h2 class="st-heading-2">Expanding Its Oncology Portfolio</h2>The acquisition will add antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) to Day One’s cancer portfolio. Emi-Le has demonstrated early anti-tumor activity in an ongoing early-stage study for an aggressive cancer called adenoid cystic carcinoma type-1.Day One believes that Emi-Le is well-positioned for potential rapid development and commercialization and expects its financial profile to aid the development of it through potential approval with no additional financing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRSN jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.MRSN stock is down by 75% this year and by 87% over the past 12 months. Meanwhile, DAWN stock has lost 18% this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ford-gears-up-for-wider-bluecruise-rollout-across-europe-in-2026/cLP9TrNRE3g">Ford Gears Up For Wider BlueCruise Rollout Across Europe In 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal

The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday.

Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

JPMorgan Chase & Co. lifted their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an "overweight" rating in a research report on Friday...

Day One Biopharmaceuticals (NASDAQ:DAWN) Trading 8.5% Higher - Here's Why

Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 8.5% - Still a Buy...

Equities Analysts Issue Forecasts for DAWN FY2025 Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - HC Wainwright raised their FY2025 earnings per share estimates for Day One Biopharmaceuticals in a report released on Wednesday...

What is Wedbush's Estimate for DAWN FY2025 Earnings?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Equities research analysts at Wedbush increased their FY2025 earnings per share (EPS) estimates for shares of Day One Biopharmaceuticals...

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

DAWN
Day One Biopharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest DAWN News

DAWNDay One Biopharmaceuticals Inc